Literature DB >> 16413538

Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274).

Seung-Jin Lee1, Byeong-Churl Jang, Soo-Woong Lee, Young-Il Yang, Seong-Il Suh, Yeong-Min Park, Sangtaek Oh, Jae-Gook Shin, Sheng Yao, Lieping Chen, In-Hak Choi.   

Abstract

Majority of cancer cells upregulate co-inhibitory molecule B7-H1 which confers resistance to anti-tumor immunity, allowing cancers to escape from host immune surveillance. We addressed the molecular mechanism underlying the regulation of cancer-associated B7-H1 expression in response to interferon-gamma (IFN-gamma). Using promoter constructs in luciferase assay, the region between 202 and 320 bp from the translational start site is responsible for B7-H1 expression. Electrophoretic mobility shift assay, site-directed mutagenesis and knockdown experiment using siRNA revealed that interferon regulatory factor-1 (IRF-1) is primarily responsible for the constitutive B7-H1 expression as well as for the IFN-gamma-mediated B7-H1 upregulation in a human lung cancer cell line A549. Additionally, AG490, a Janus activated kinase/signal transducer and activator of transcription inhibitor, greatly abolished the responsiveness of A549 cells to IFN-gamma by reducing the IRF-1 transcription. Our findings support a critical role of IRF-1 in the regulation of constitutive and IFN-gamma-induced expression of B7-H1 in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16413538     DOI: 10.1016/j.febslet.2005.12.093

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  203 in total

1.  Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1.

Authors:  Kiyoshi Hirahara; Kamran Ghoreschi; Xiang-Ping Yang; Hayato Takahashi; Arian Laurence; Golnaz Vahedi; Giuseppe Sciumè; Aisling O'Hara Hall; Christopher D Dupont; Loise M Francisco; Qian Chen; Masao Tanaka; Yuka Kanno; Hong-Wei Sun; Arlene H Sharpe; Christopher A Hunter; John J O'Shea
Journal:  Immunity       Date:  2012-06-21       Impact factor: 31.745

2.  Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.

Authors:  Ailing Wu; Qingzhe Wu; Yujie Deng; Yuning Liu; Jinqiu Lu; Liansheng Liu; Xiaoling Li; Cheng Liao; Bin Zhao; Hai Song
Journal:  EMBO J       Date:  2018-11-05       Impact factor: 11.598

3.  Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Authors:  Ben C Creelan; Scott Antonia; David Noyes; Terri B Hunter; George R Simon; Gerold Bepler; Charles C Williams; Tawee Tanvetyanon; Eric B Haura; Michael J Schell; Alberto Chiappori
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

4.  IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.

Authors:  Wei Xiao; John D Klement; Chunwan Lu; Mohammed L Ibrahim; Kebin Liu
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

5.  A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.

Authors:  Samuel T Haile; Lucas A Horn; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Res       Date:  2014-04-02       Impact factor: 11.151

Review 6.  Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Authors:  Kim A Reiss; Patrick M Forde; Julie R Brahmer
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

7.  CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.

Authors:  Hadas Lewinsky; Avital F Barak; Victoria Huber; Matthias P Kramer; Lihi Radomir; Lital Sever; Irit Orr; Vita Mirkin; Nili Dezorella; Mika Shapiro; Yosef Cohen; Lev Shvidel; Martina Seiffert; Yair Herishanu; Shirly Becker-Herman; Idit Shachar
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

8.  Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Authors:  Mohammad Atefi; Earl Avramis; Amanda Lassen; Deborah J L Wong; Lidia Robert; David Foulad; Michael Cerniglia; Bjoern Titz; Thinle Chodon; Thomas G Graeber; Begonya Comin-Anduix; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

9.  Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion.

Authors:  Xue Pan; Anyuan Zhong; Yufei Xing; Minhua Shi; Bin Qian; Tong Zhou; Yongjing Chen; Xueguang Zhang
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

Review 10.  Genomic Approaches to Understanding Response and Resistance to Immunotherapy.

Authors:  David A Braun; Kelly P Burke; Eliezer M Van Allen
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.